Rocket Pharmaceuticals (RCKT) Asset Writedowns and Impairment (2017 - 2020)
Rocket Pharmaceuticals (RCKT) posted Asset Writedowns and Impairment of -$1000.0 for Q2 2020, down 101.59% sequentially from $63000.0 in Q1 2020.
Powered by 
Analysis
Rocket Pharmaceuticals (RCKT) Asset Writedowns and Impairment (2017 - 2020) Analysis & Trends
Rocket Pharmaceuticals has reported Asset Writedowns and Impairment for 4 years, with the latest figure at -$1000.0 in Q2 2020.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to -$1000.0 in Q2 2020, while the trailing twelve-month figure through Dec 2023 was -$1000.0 (down 101.61% YoY) and the FY2025 annual result came in at $262000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment slipped to -$1000.0 in Q2 2020 per RCKT's latest filing, from $63000.0 in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $63000.0 in Q1 2020 and troughed at -$1000.0 in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Rocket Pharmaceuticals | 437.27 Mn | 437.27 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2020 | -1,000.00 |
| Mar 31, 2020 | 63,000.00 |
| Dec 31, 2017 | 14,000.00 |